GMAB vs DOW Comparison

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Dow is one of the largest plastics and chemicals producers in the world, ranking in the top five for upstream plastics production, such as polyethylene, or PE, and polypropylene, or PP. It has three reportable segments: packaging and specialty plastics (P&SP), industrial intermediates and infrastructure (II&I), and performance materials and coatings (PM&C). The company traces its roots to 1897 with the founding of the Dow Chemical Company. After a long history of chemical production, Dow strategically merged with DuPont in 2017. In 2019, Dow, DuPont, and Corteva were split to enhance operational focus on the assets of the chemical conglomerate.